Stay updated on Expanded Access to Upadacitinib Clinical Trial
Sign up to get notified when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.

Latest updates to the Expanded Access to Upadacitinib Clinical Trial page
- Check7 days agoChange DetectedNo textual changes were detected; the page's Expanded Access details for Upadacitinib remain unchanged.SummaryDifference0.3%

- Check14 days agoChange DetectedThe page revision has been bumped from v3.6.5 to v3.6.6, indicating a newer version of the page has been published.SummaryDifference0.3%

- Check21 days agoChange DetectedExpanded Access page now lists additional eligible conditions for Upadacitinib (e.g., Hidradenitis Suppurativa, Vitiligo, Alopecia Areata, Systemic Lupus Erythematosus, Giant Cell Arteritis, Spondyloarthritis, Axial Spondyloarthritis, Psoriatic Arthritis, Rheumatoid Arthritis) and updates related MeSH terms. Older date entries (2026-01-30, 2026-01-29, 2025-04) were removed.SummaryDifference5%

- Check28 days agoNo Change Detected
- Check36 days agoChange DetectedThe page revision was updated from v3.6.4 to v3.6.5, indicating a small platform update to the UI/backend. No study details or user actions are altered by this change.SummaryDifference0.1%

- Check50 days agoChange DetectedThe page shows a new Revision: v3.6.4 label, replacing the previous v3.6.3. This reflects a minor behind-the-scenes update to the site version rather than changes to the study information.SummaryDifference0.1%

- Check71 days agoChange DetectedRevision: v3.6.3 replaces the prior Revision: v3.6.2, reflecting a new site revision. This is a minor update to the page's revision metadata rather than changes to the study details.SummaryDifference0.1%

Stay in the know with updates to Expanded Access to Upadacitinib Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Expanded Access to Upadacitinib Clinical Trial page.